Sylvia Jaramillo is an Oncology physician. OpenAlex indexes 5 publications with 382 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12221 Renfert Way
Suite 300
Austin, TX 787585444
Telephone
512-873-8900Registry record last updated 23 Oct 2017.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20258 payments
- Merck Sharp & Dohme LLCProgram year20255 payments
- E.R. Squibb & Sons, L.L.C.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
40.8%Microtubule Inhibitor21.5%Paclitaxel100%Part B, office-administered≥33 patientsPD-1 inhibitor17.3%Pembrolizumab91%Dostarlimab-gxly10%Part B, office-administered≥19 patients+ 7 more classes in this area
Metabolism & gastrointestinal
33%Other antiemetics28%Fosaprepitant100%Part B, office-administered≥58 patientsSerotonin-3 Receptor Antagonist3.3%Palonosetron hcl63%Granisetron hydrochloride36%Ondansetron Hcl1%Ondansetron Odt1%Part D + Part B<11 patients+ 4 more classes in this area
Blood & clotting
21.9%Parenteral Iron Replacement21.4%Iron sucrose100%Part B, office-administered≥34 patientsFactor Xa inhibitor0.4%Eliquis64%Xarelto36%Part D≥36 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gastroesophageal Cancer During Pregnancy: a Case Report and Review of the Literature
Journal of Gastrointestinal Cancer
2018 - Current and Emerging Therapies in Peripheral T-cell Lymphoma: Focus on Pralatrexate
Clinical Medicine Insights Therapeutics
2011 - Hospitalization after hepatic artery embolization (HAE) for neuroendocrine tumors (NET).
Journal of Clinical Oncology
2011
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”